Search Results - "MOHAPI, Lerato"

One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis by Swindells, Susan, Ramchandani, Ritesh, Gupta, Amita, Benson, Constance A, Leon-Cruz, Jorge, Mwelase, Noluthando, Jean Juste, Marc A, Lama, Javier R, Valencia, Javier, Omoz-Oarhe, Ayotunde, Supparatpinyo, Khuanchai, Masheto, Gaerolwe, Mohapi, Lerato, da Silva Escada, Rodrigo O, Mawlana, Sajeeda, Banda, Peter, Severe, Patrice, Hakim, James, Kanyama, Cecilia, Langat, Deborah, Moran, Laura, Andersen, Janet, Fletcher, Courtney V, Nuermberger, Eric, Chaisson, Richard E

“…Treatment of latent tuberculosis infection is an important control measure, especially in patients coinfected with HIV. In this international phase 3 trial, 1…”
Get full text

Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis by Havlir, Diane V, Kendall, Michelle A, Ive, Prudence, Kumwenda, Johnstone, Swindells, Susan, Qasba, Sarojini S, Luetkemeyer, Anne F, Hogg, Evelyn, Rooney, James F, Wu, Xingye, Hosseinipour, Mina C, Lalloo, Umesh, Veloso, Valdilea G, Some, Fatuma F, Kumarasamy, N, Padayatchi, Nesri, Santos, Breno R, Reid, Stewart, Hakim, James, Mohapi, Lerato, Mugyenyi, Peter, Sanchez, Alejandro, Sanchez, Jorge, Lama, Javier R, Pape, Jean W, Asmelash, Aida, Moko, Evans, Sawe, Fred, Andersen, Janet, Sanne, Ian

“…In this international study involving 809 patients with HIV and TB coinfection, earlier therapy for both infections, versus waiting 8 to 12 weeks to initiate…”
Get full text

Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study by Tweed, Conor Duncan, Wills, Genevieve Helen, Crook, Angela M, Dawson, Rodney, Diacon, Andreas H, Louw, Cheryl E, McHugh, Timothy D, Mendel, Carl, Meredith, Sarah, Mohapi, Lerato, Murphy, Michael E, Murray, Stephen, Murthy, Sara, Nunn, Andrew J, Phillips, Patrick P J, Singh, Kasha, Spigelman, M, Gillespie, S H

“…Drug-induced liver injury (DILI) is a common complication of tuberculosis treatment. We utilised data from the REMoxTB clinical trial to describe the incidence…”
Get full text

Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial by Hosseinipour, Mina C, Prof, Bisson, Gregory P, MD, Miyahara, Sachiko, PhD, Sun, Xin, MS, Moses, Agnes, MMED, Riviere, Cynthia, MD, Kirui, Fredrick K, MMED, Badal-Faesen, Sharlaa, MBBCh, Lagat, David, MBChB, Nyirenda, Mulinda, MMED, Naidoo, Kogieleum, MBChB, Hakim, James, Prof, Mugyenyi, Peter, Prof, Henostroza, German, MD, Leger, Paul D, MD, Lama, Javier R, MD, Mohapi, Lerato, MBBCh, Alave, Jorge, MD, Mave, Vidya, MD, Veloso, Valdilea G, MD, Pillay, Sandy, MBChB, Kumarasamy, Nagalingeswaran, PhD, Bao, Jing, MD, Hogg, Evelyn, BA, Jones, Lynne, MT ASCP, Zolopa, Andrew, Prof, Kumwenda, Johnstone, Prof, Gupta, Amita, MD

“…Summary Background Mortality within the first 6 months after initiating antiretroviral therapy is common in resource-limited settings and is often due to…”
Get full text

Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa : a prospective cohort by GOLUB, Jonathan E, PRONYK, Paul, MOHAPI, Lerato, THSABANGU, Nkeko, MOSHABELA, Mosa, STRUTHERS, Helen, GRAY, Glenda E, MCLNTYRE, James A, CHAISSON, Richard E, MARTINSON, Neil A

“…The World Health Organization recommends isoniazid preventive therapy (IPT) for preventing tuberculosis in HIV-infected adults, although few countries have…”
Get full text

Factors Associated With and Characteristic of HIV/Tuberculosis Co-Infection: A Retrospective Analysis of SECOND-LINE Clinical Trial Participants by Henry, Rebecca T., Jiamsakul, Awachana, Law, Matthew, Losso, Marcelo, Kamarulzaman, Adeeba, Phanuphak, Praphan, Kumarasamy, Nagalingeswaran, Foulkes, Sharne, Mohapi, Lerato, Nwizu, Chidi, Wood, Robin, Kelleher, Anthony, Polizzotto, Mark

“…Tuberculosis (TB) is a common infection in people living with HIV. However, the risk factors for HIV/TB co-infection in second-line HIV therapy are poorly…”
Get full text

Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa by El-Khatib, Ziad, Katzenstein, David, Marrone, Gaetano, Laher, Fatima, Mohapi, Lerato, Petzold, Max, Morris, Lynn, Ekström, Anna Mia

“…Affordable strategies to prevent treatment failure on first-line regimens among HIV patients are essential for the long-term success of antiretroviral therapy…”
Get full text

Integrative Multi-Omics Reveals Serum Markers of Tuberculosis in Advanced HIV by Krishnan, Sonya, Queiroz, Artur T L, Gupta, Amita, Gupte, Nikhil, Bisson, Gregory P, Kumwenda, Johnstone, Naidoo, Kogieleum, Mohapi, Lerato, Mave, Vidya, Mngqibisa, Rosie, Lama, Javier R, Hosseinipour, Mina C, Andrade, Bruno B, Karakousis, Petros C

“…Tuberculosis (TB) accounts for disproportionate morbidity and mortality among persons living with HIV (PLWH). Conventional methods of TB diagnosis, including…”
Get full text

Body mass index and risk of tuberculosis and death by HANRAHAN, Colleen F, GOLUB, Jonathan E, MOHAPI, Lerato, TSHABANGU, Nkeko, MODISENYANE, Tebogo, CHAISSON, Richard E, GRAY, Glenda E, MCINTYRE, James A, MARTINSON, Neil A

“…High BMI has been shown to be protective against tuberculosis (TB) among HIV-uninfected individuals, as well as against disease progression and mortality among…”
Get full text

CD4 counts and viral loads of newly diagnosed HIV-infected individuals: implications for treatment as prevention by Govender, Sarishen, Otwombe, Kennedy, Essien, Thandekile, Panchia, Ravindre, de Bruyn, Guy, Mohapi, Lerato, Gray, Glenda, Martinson, Neil

“…To report the viral load and CD4 count in HIV-infected, antiretroviral naïve, first -time HIV-testers, not immediately eligible for treatment initiation by…”
Get full text

Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection by Amin, Janaki, Boyd, Mark A, Kumarasamy, Nagalingeswaran, Moore, Cecilia L, Losso, Marcello H, Nwizu, Chidi A, Mohapi, Lerato, Kerr, Stephen J, Sohn, Annette H, Teppler, Hedy, Renjifo, Boris, Molina, Jean-Michel, Emery, Sean, Cooper, David A

“…To determine the durability over 96 weeks of safety and efficacy of lopinavir/ritonavir (LPV/r) and raltegravir (RAL) which was demonstrated to have…”
Get full text

Progression and regression of premalignant cervical lesions in HIV-infected women from Soweto: a prospective cohort by OMAR, Tanvier, SCHWARTZ, Sheree, HANRAHAN, Colleen, MODISENYANE, Tebogo, TSHABANGU, Nkeko, GOLUB, Jonathan E, MCINTYRE, James A, GRAY, Glenda E, MOHAPI, Lerato, MARTINSON, Neil A

“…To ascertain progression and regression of cervical dysplasia in HIV-infected women in Soweto. Prospective cohort. Women attending an HIV wellness clinic were…”
Get full text

Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial by Lockman, Shahin, Hughes, Michael, Sawe, Fred, Zheng, Yu, McIntyre, James, Chipato, Tsungai, Asmelash, Aida, Rassool, Mohammed, Kimaiyo, Sylvester, Shaffer, Douglas, Hosseinipour, Mina, Mohapi, Lerato, Ssali, Francis, Chibowa, Margret, Amod, Farida, Halvas, Elias, Hogg, Evelyn, Alston-Smith, Beverly, Smith, Laura, Schooley, Robert, Mellors, John, Currier, Judith

“…Nevirapine (NVP) is widely used in antiretroviral treatment (ART) of HIV-1 globally. The primary objective of the AA5208/OCTANE trial was to compare the…”
Get full text

The effect of a maturing antiretroviral program on early mortality for patients with advanced immune-suppression in Soweto, South Africa by Otwombe, Kennedy N, Laher, Fatima, Tutu-Gxashe, Thandeka, Gray, Glenda, Mohapi, Lerato

“…We hypothesize that time to initiate care and maturity of a treatment program impact on outcome of severely immuno-compromised patients with higher risk of…”
Get full text

Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status by Tweed, Conor D, Crook, Angela M, Dawson, Rodney, Diacon, Andreas H, McHugh, Timothy D, Mendel, Carl M, Meredith, Sarah K, Mohapi, Lerato, Murphy, Michael E, Nunn, Andrew J, Phillips, Patrick P J, Singh, Kasha P, Spigelman, Melvin, Gillespie, Stephen H

“…The phase III REMoxTB study prospectively enrolled HIV-positive (with CD4+ count > 250 cells, not on anti-retroviral therapy) and HIV-negative patients. We…”
Get full text

Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection by Amin, Janaki, Boyd, Mark A, Kumarasamy, Nagalingeswaran, Moore, Cecilia L, Losso, Marcello H, Nwizu, Chidi A, Mohapi, Lerato, Kerr, Stephen J, Sohn, Annette H, Teppler, Hedy, Renjifo, Boris, Molina, Jean-Michel, Emery, Sean, Cooper, David A

Get full text

Switching at low HIV-1 RNA into fixed dose combinations : TDF/FTC/RPV is non-inferior to TDF/FTC/ EFV in first-line suppressed patients living with HIV by Mohapi, Lerato, Bicer, Ceyhun, Munderi, Paula, Mbida, Pascale A.M., Jansen, Marjolein, Van Delft, Yvon, Mohammed, Perry, Moussa, Samba B., Avihingsanon, Anchalee, Were, Edwin

“…Background: In low- and middle-income countries (LMICs), a substantial unmet need for affordable single-tablet regimen (STR) options remains. Rilpivirine (RPV,…”
Get full text

Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study by Boyd, Mark A, Prof, Amin, Janaki, PhD, Mallon, Patrick W G, PhD, Kumarasamy, Nagalingeswaran, MD, Lombaard, Johan, MD, Wood, Robin, Prof, Chetchotisakd, Ploenchan, Prof, Phanuphak, Praphan, Prof, Mohapi, Lerato, MD, Azwa, Iskandar, MD, Belloso, Waldo H, MD, Molina, Jean-Michel, Prof, Hoy, Jennifer, Prof, Moore, Cecilia L, MIPH, Emery, Sean, Prof, Cooper, David A, Prof

“…Summary Background Lipoatrophy is one of the most feared complications associated with the use of nucleoside or nucleotide reverse transcriptase inhibitors…”
Get full text

STRETCHing delivery of HIV health services by Boyd, Mark, Mohapi, Lerato

“…In The Lancet, Lara Fairall and colleagues7 present a cluster-randomised trial done in the Free State province of South Africa that tested task shifting of ART…”
Get full text

Using a domain specific language for SDR to facilitate radar signal processing in heterogeneous computing architectures by Mohapi, Lerato J., Winberg, Simon, Inggs, Michael

“…This paper presents the use of a Domain-Specific Language (DSL) for Software Defined Radio (SDR) in a Radar digital signal processing (DSP) using heterogeneous…”
Get full text